Synthetic Nanoparticles for Vaccines and Immunotherapy
Name
Irvine_Synthetic nanoparticles.pdf
Size
5.48 MB
Format
Adobe PDF
Checksum (MD5)
543b2f38af237447d91c332d4b4b5008
Author(s)
Rakhra, Kavya
Tokatlian, Talar
Irvine, Darrell J
Hanson, Melissa Catherine
Date Issued
October 2015
Journal
Chemical Reviews
Publisher
American Chemical Society (ACS)
Citation
Irvine, Darrell J., Melissa C. Hanson, Kavya Rakhra, and Talar Tokatlian. “Synthetic Nanoparticles for Vaccines and Immunotherapy.” Chemical Reviews 115, no. 19 (October 14, 2015): 11109–11146. © 2015 American Chemical Society
Version
Author's final manuscript
Abstract
The immune system plays a critical role in our health. No other component of human physiology plays a decisive role in as diverse an array of maladies, from deadly diseases with which we are all familiar to equally terrible esoteric conditions: HIV, malaria, pneumococcal and influenza infections; cancer; atherosclerosis; autoimmune diseases such
as lupus, diabetes, and multiple sclerosis. The importance of understanding the function of the immune system and learning how to modulate immunity to protect against or treat disease thus cannot be overstated. Fortunately, we are entering an exciting era where the
science of immunology is defining pathways for the rational manipulation of the immune system at the cellular and molecular level, and this understanding is leading to dramatic advances in the clinic that are transforming the future of medicine.1,2 These initial advances are being made primarily through biologic drugs– recombinant proteins (especially antibodies) or patient-derived cell therapies– but exciting data from preclinical studies suggest that a marriage of approaches based in biotechnology with the materials science and chemistry of nanomaterials, especially nanoparticles, could enable more effective and safer immune engineering strategies. This review will examine these nanoparticle-based strategies to immune modulation in detail, and discuss the promise and outstanding challenges facing the field of immune engineering from a chemical biology/materials engineering perspective
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Ragon Institute of MGH, MIT and Harvard
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1021/acs.chemrev.5b00109
